scholarly journals Orally Administered NSAIDs—General Characteristics and Usage in the Treatment of Temporomandibular Joint Osteoarthritis—A Narrative Review

2021 ◽  
Vol 14 (3) ◽  
pp. 219
Author(s):  
Marcin Derwich ◽  
Maria Mitus-Kenig ◽  
Elzbieta Pawlowska
Keyword(s):  
Temporomandibular Joint ◽  
Diclofenac Sodium ◽  
Narrative Review ◽  
Joint Disease ◽  
Gastrointestinal Complications ◽  
Pubmed Database ◽  
Increased Risk ◽  
Temporomandibular Joint Osteoarthritis ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Background: Temporomandibular joint osteoarthritis (TMJ OA) is a degenerative joint disease. The aim of this review was to present the general characteristics of orally administered nonsteroidal anti-inflammatory drugs (NSAIDs) and to present the efficacy of NSAIDs in the treatment of TMJ OA. Methods: PubMed database was analyzed with the keywords: “(temporomandibular joint) AND ((disorders) OR (osteoarthritis) AND (treatment)) AND (nonsteroidal anti-inflammatory drug)”. After screening of 180 results, 6 studies have been included in this narrative review. Results and Conclusions: Nonsteroidal anti-inflammatory drugs are one of the most commonly used drugs for alleviation of pain localized in the orofacial area. The majority of articles predominantly examined and described diclofenac sodium in the treatment of pain in the course of TMJ OA. Because of the limited number of randomized studies evaluating the efficacy of NSAIDs in the treatment of TMJ OA, as well as high heterogeneity of published researches, it seems impossible to draw up unequivocal recommendations for the usage of NSAIDs in the treatment of TMJ OA. However, it is highly recommended to use the lowest effective dose of NSAIDs for the shortest possible time. Moreover, in patients with increased risk of gastrointestinal complications, supplementary gastroprotective agents should be prescribed.

Impact of Medication with Diclofenac Sodium vs. Etoricoxibum in Patients with Inflammatory Reumatic Pathology, Prosthetic Complications and Algo-dysfunctional Syndrome

2017 ◽  
Vol 68 (5) ◽  
pp. 977-981
Author(s):  
Laura Elisabeta Checherita ◽  
Elena Rezus ◽  
Maria Magdalena Leon ◽  
Ovidiu Stamatin ◽  
Elena Mihaela Carausu
Keyword(s):  
Drug Treatment ◽  
Temporomandibular Joint ◽  
Diclofenac Sodium ◽  
Symptomatic Treatment ◽  
Daily Dose ◽  
Before And After ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Prosthetic Complications ◽  
Important Objective

Affections of temporomandibular joint (TMJ) can lead to imbalances and disfunctions named algodisfunctional syndrome. One of the affections that we will take into consideration in this study is the temporal-mandibular arthrosis, which is, in fact, the frequent pathology at this level, and to which we will measure the pain before and after the administration of the anti-inflammatory therapy: Etoricoxib vs. Dyclofenac.The important objective of this study is to investigate this type of drug treatment over TMJ. The class of drug called non-steroidal anti-inflammatory drugs (NSAIDs)�so called to distinguish this class of drug from steroids, which have similar but additional effects�make NSAIDs one of frequently used drugs for the symptomatic treatment of many common conditions. Etoricoxib is clinically effective in the therapy of TMJ providing a magnitude of effect comparable to that of the maximum recommended daily dose of Diclofenac.

scholarly journals Antinociceptive and Anti-inflammatory Effects of Combined Administration of a-tocopherol and Diclofenac

2015 ◽  
Vol 10 (1) ◽  
pp. 30-35
Author(s):  
Tasneema Juaira ◽  
Noorzahan Begum ◽  
Taskina Ali
Keyword(s):  
Body Weight ◽  
Diclofenac Sodium ◽  
Control Group ◽  
Gastrointestinal Complications ◽  
Combined Administration ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Post Hoc ◽  
Medical University ◽  
Experimental Group

Background: Nonsteroidal anti-inflammatory drugs such as diclofenac are used for relief of pain and inflammation, but frequently cause gastrointestinal complications. This study aimed to explore that combination of diclofenac and ?-tocopherol (áT) are better analgesic as well as anti-inflammatory agent than that of diclofenac alone.Objective: To assess the effects of combination of diclofenac with á-tocopherol on pain and inflammation.Methods: This prospective experimental study was conducted in the Department of Physiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbag, Dhaka between January to December 2013. For this purpose, 15 male Long Evans rats were studied. On the basis of vitamin and drug administrations, the rats were divided into three (3) groups (5 rats in each). Control group received normal saline, one experimental group received diclofenac sodium (DS) at a dose of 10 mg/kg/body weight, and another experimental group received combination of DS with áT at a dose of 10 mg/kg/body weight and 500mg/kg/body weight, respectively. All the groups received single dose and equal volume (1 ml) through intraperitoneal route 1 hour before the test. Just one hour after administrations, they were subjected to formalin test followed by formalin induced paw edema test. The data were statistically analyzed by ANOVA followed by Bonferroni Post Hoc test.Results: Combined administration of DS and áT significantly (p<0.001) lowered the variables for nociceptive pain, central analgesic activity, inflammatory pain and inflammation than individual intervention of DS.Conclusion: From this study it may be concluded that, combined administration of diclofenac sodium and ±-tocopherol were more effective in lowering pain and inflammation than individual administration of diclofenac.Bangladesh Soc Physiol. 2015, June; 10(1): 30-35

scholarly journals Recommendations for the Appropriate Use of Anti-Inflammatory Drugs in the Era of the Coxibs: Defining the Role of Gastroprotective Agents

2002 ◽  
Vol 16 (4) ◽  
pp. 231-240 ◽  
Author(s):  
Richard H Hunt ◽  
Alan N Barkun ◽  
David Baron ◽  
Claire Bombardier ◽  
Ford R Bursey ◽  
...  
Keyword(s):  
Analgesic Efficacy ◽  
Dual Therapy ◽  
Protective Agent ◽  
Appropriate Use ◽  
Gastrointestinal Complications ◽  
Conventional Nsaid ◽  
Gastrointestinal Lesions ◽  
Increased Risk ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Treatment with anti-inflammatory drugs and the analgesic efficacy of conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are compromised by a two- to fourfold increased risk of gastrointestinal complications. This increased risk has resulted in an increasing use of the new selective cyclooxygenase-2 inhibitors or coxibs, which, in clinical trials and outcomes studies, reduced gastrointestinal adverse events by 50% to 65% compared with conventional NSAIDs. However, the coxibs are not available to all patients who need them, and NSAIDs are still widely used. Moreover, treatment with a coxib cannot heal pre-existing gastrointestinal lesions, and cotherapy with an anti-secretory drug or mucosal protective agent may be required.This paper addresses the management of patients with risk factors for gastrointestinal complications who are taking NSAIDs and makes recommendations for the appropriate use of ‘gastroprotective’ agents (GPAs) in patients who need to take an NSAID or a coxib. When economically possible, a coxib alone is preferable to a conventional NSAID plus a GPA to minimize exposure to potential gastrointestinal damage and avoid unnecessary dual therapy. Patients at high risk require a GPA in addition to a coxib.

scholarly journals Safety of selective non-steroidal anti-inflammatory drugs: analysis of the last years data

The Clinician ◽  
2020 ◽  
Vol 14 (1-2) ◽  
pp. 91-99
Author(s):  
N. A. Shostak ◽  
A. A. Klimenko ◽  
N. A. Demidova ◽  
D. A. Anichkov
Keyword(s):  
Heart Failure ◽  
Gastrointestinal Tract ◽  
Side Effects ◽  
Adverse Events ◽  
Gastrointestinal Complications ◽  
Increased Risk ◽  
Inflammatory Drugs ◽  
Cox 2 ◽  
Anti Inflammatory ◽  
Cox 2 Inhibitors

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly used pain relievers. However, their use often threatens with serious undesirable effects, associated mainly with damage to cardiovascular system (CVS), gastrointestinal tract, kidneys and liver. Contraindications to NSAIDs prescription are clearly regulated, algorithms for their personalized appointment are determined taking into account risk factors for cardiovascular and gastrointestinal adverse events. The severity of NSAIDs side effects is mainly due to the selectivity to cyclooxygenase-2 (COX-2), as well as the physicochemical properties of various drugs. Cardiovascular adverse events differ among various NSAIDs both within commonly used drugs and among COX-2 inhibitors. It is well known that NSAIDs selective for COX-2 are safer in terms of the effect on the gastrointestinal tract than non-selective drugs. A meta-analysis showed that relatively selective COX-2 inhibitors (meloxicam, etodolac) were associated with a comparable risk of developing symptomatic ulcers and ulcers identified by endoscopy, and safety and tolerability profiles of the drugs were similar.All NSAIDs are associated with cardiovascular toxicity, however, different drugs have significant risk differences. The mechanism of NSAIDs cardiovascular adverse effects is associated with an increase of blood pressure, sodium retention, vasoconstriction, platelet activation, and prothrombotic state. It has been shown that the risk of cardiovascular adverse events when taking COX-2 inhibitors (celecoxib, etoricoxib) significantly increases. According to a study of more than 8 million people, it was found that the risk of myocardial infarction was increased in patients taking ketorolac. Further, highest to lowest risk authors list indomethacin, etoricoxib, rofecoxib (not currently used), diclofenac, a fixed combination of diclofenac with misoprostol, piroxicam, ibuprofen, naproxen, celecoxib, meloxicam, nimesulide and ketoprofen. When taking NSAIDs, the risk of heart failure decompensation increases, and it turned out to be the greatest for ketorolac, etoricoxib, and indomethacin. Meloxicam, aceclofenac, ketoprofen almost did not increase heart failure risk. It should be noted that when using the drugs (except for indomethacin and meloxicam), there is a tendency to increase the total cardiovascular and renal risks with increasing doses. Thus, it is obvious that a very careful approach is required when choosing NSAIDs. If there is an increased risk of gastrointestinal complications associated with NSAIDs, selective NSAIDs are preferred, with both coxibs and traditional selective NSAIDs showing the best safety profile in the studies. To minimize cardiovascular side effects specialists should consider the risk level of cardiovascular complications, as well as results of large clinical studies where particular NSAIDs are compared.

Abstract 3047: What Are the Effects of Nonsteroidal Anti-Inflammatory Drugs on Post-Cardiothoracic Surgery Outcomes?

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Richard T Ruffin ◽  
Jeffrey Kluger ◽  
Stephanie M Wills ◽  
C M White ◽  
Craig I Coleman
Keyword(s):  
Atrial Fibrillation ◽  
Cardiothoracic Surgery ◽  
Red Blood Cell Transfusion ◽  
Beta Blockade ◽  
Randomized Controlled ◽  
Conflicting Evidence ◽  
Increased Risk ◽  
Inflammatory Drugs ◽  
Surgery Outcomes ◽  
Anti Inflammatory

Background: Two previous studies evaluating nonsteroidal anti-inflammatory drug (NSAID) use following cardiothoracic surgery (CTS) demonstrated conflicting evidence regarding their ability to reduce the incidence of postoperative atrial fibrillation (POAF). Moreover, neither study examined negative cardiovascular outcomes such as stroke and myocardial infarction (MI). Since a recent study evaluating paracoxib/valdecoxib following CTS demonstrated an increased risk of cardiovascular events, we sought to evaluate whether NSAIDs could reduce the incidence of POAF without increasing patients’ risk of stroke or MI. Methods: Patients (n=555) undergoing CTS from the randomized, controlled Atrial Fibrillation Suppression Trials (AFISTs) I, II and III were evaluated in this nested study. Demographic, surgical and medication use characteristics were prospectively collected as part of the AFIST trials. Endpoints included POAF, stroke, MI and the need for red blood cell transfusion. Multivariable logistic regression was used to calculate odds ratios with 95% confidence intervals. Results: The population was 67.8 ± 8.6 years old, 77.1% male, 14.6% underwent valve surgery, 6.1% had prior AF, 12.6% had heart failure and 84.0% and 44.1% received postoperative beta-blockade and prophylactic amiodarone. In total, 127 (22.9%) patients received a NSAID postoperatively. NSAID use was associated with reductions in the odds of POAF and the need for RBC transfusions. (Table ) No elevation in the odds of developing stroke or MI was observed. Conclusions: NSAIDs decreased the odds of developing POAF and the need for RBC transfusions without significantly increasing MI or stroke. Table. Effect of Nonsteroidal Anti-Inflammatory Drugs on Postoperative Outcomes

scholarly journals Effects of anti-inflammatory drugs on the responses of C-polymodal nociceptors in the temporomandibular joint

PAIN RESEARCH ◽  
2004 ◽  
Vol 19 (4) ◽  
pp. 167-172
Author(s):  
Tomohiro Ohara ◽  
Jorge L. Zeredo ◽  
Kosuke Miura ◽  
Rie Fujiyama ◽  
Yukio Okada ◽  
...  
Keyword(s):  
Temporomandibular Joint ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

scholarly journals Rheumatoid arthritis: influence of inflammation and anti-inflammatory therapy on cardiovascular risk factors

2020 ◽  
pp. 32-44
Author(s):  
D. I. Trukhan ◽  
D. S. Ivanova ◽  
K. D. Belus
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factors ◽  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
Cardiovascular Risk Factors ◽  
Chronic Inflammation ◽  
Pharmacological Intervention ◽  
Increased Risk ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Rheumatoid arthritis is a frequent and one of the most severe immuno-inflammatory diseases in humans, which determines the great medical and socio-economic importance of this pathology. One of the priority problems of modern cardiac rheumatology is an increased risk of cardiovascular complications in rheumatoid arthritis. In patients with rheumatoid arthritis, traditional cardiovascular risk factors for cardiovascular diseases (metabolic syndrome, obesity, dyslipidemia, arterial hypertension, insulin resistance, diabetes mellitus, smoking and hypodynamia) and a genetic predisposition are expressed. Their specific features also have a certain effect: the “lipid paradox” and the “obesity paradox”. However, chronic inflammation as a key factor in the development of progression of atherosclerosis and endothelial dysfunction plays a leading role in morbidity and mortality from cardiovascular diseases in rheumatoid arthritis. This review discusses the effect of chronic inflammation and its mediators on traditional cardiovascular risk factors and its independent significance in the development of CVD. Drug therapy (non-steroidal anti-inflammatory drugs, glucocorticosteroids, basic anti-inflammatory drugs, genetically engineered biological drugs) of the underlying disease also has a definite effect on cardiovascular risk factors in patients with rheumatoid arthritis. A review of studies on this problem suggests a positive effect of pharmacological intervention in rheumatoid arthritis on cardiovascular risk factors, their reduction to a level comparable to the populations of patients not suffering from rheumatoid arthritis. The interaction of rheumatologists, cardiologists and first-contact doctors (therapist and general practitioner) in studying the mechanisms of the development of atherosclerosis in patients with rheumatoid arthritis will allow in real clinical practice to develop adequate methods for the timely diagnosis and prevention of cardiovascular diseases in patients with rheumatoid arthritis.

scholarly journals Nonsteroidal Anti-inflammatory Drugs and Increased Risk of Acute Urinary Retention

2005 ◽  
Vol 165 (13) ◽  
pp. 1547 ◽  
Author(s):  
Katia M. C. Verhamme ◽  
Jeanne P. Dieleman ◽  
Marc A. M. Van Wijk ◽  
Johan van der Lei ◽  
Joseph L. H. R. Bosch ◽  
...  
Keyword(s):  
Urinary Retention ◽  
Acute Urinary Retention ◽  
Increased Risk ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Effect of Some Anti-Inflammatory Drugs on Human Neutrophil Chemotaxis

1994 ◽  
Vol 22 (2) ◽  
pp. 100-106 ◽  
Author(s):  
G Hasçelik ◽  
B ŞLener ◽  
Z Hasçelik
Keyword(s):  
Acetylsalicylic Acid ◽  
Polymorphonuclear Leukocyte ◽  
Polymorphonuclear Leukocytes ◽  
Diclofenac Sodium ◽  
Tiaprofenic Acid ◽  
Boyden Chamber ◽  
Random Migration ◽  
Leukocyte Chemotaxis ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

The effects of piroxicam, tenoxicam, diclofenac sodium, acetylsalicylic acid and tiaprofenic acid on the chemotaxis and random migration of human polymorphonuclear leukocytes were investigated, using zymosan-activated serum as chemo-attractant, with a modified Boyden chamber technique. All five compounds significantly reduced chemotaxis. The random migration of polymorphonuclear leukocytes was inhibited by piroxicam, diclofenac sodium and tiaprofenic acid but not by tenoxicam or acetylsalicylic acid. The inhibitory effect of these non-steroidal anti-inflammatory drugs on polymorphonuclear leukocyte chemotaxis and on random migration was generally dose-dependent. The results suggest that the drugs studied may have a direct effect on polymorphonuclear leukocyte chemotaxis and that this activity may contribute to their anti-inflammatory properties.

Sign in / Sign up

Export Citation Format

Share Document